About this trial
This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive
Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
Disqualifiers
None
Trial population
Patient eligible for a treatment with CAR-T for an hematological malignancy
Trial design
Cohort
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
overall survival from eligibility
Overall survival from administration
complete response rate
Progression free survival
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
The Lymphoma Academic Research Organisation
Lead sponsor
Gilead Sciences
Collaborator
Novartis
Collaborator
Bristol-Myers Squibb
Collaborator